Recall Register

Drug recall: Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-98

Class II FDA enforcement event 95611. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Cipla USA, Inc. started this drug recall on 23 Oct 2024. The firm address in the FDA record is in Warren, NJ. FDA put the recall in Class II. FDA event 95611 has 2 product records. The first FDA enforcement report date is 20 Nov 2024. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

USA nationwide.

Recalling firm

Cipla USA, Inc., Warren, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

2 product records in the event.

FDA event 95611: product records
Recall numberProductQuantityClassStatusReport date
D-0043-2025Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-981,875 boxes (cipla and exlan)Class IIOngoing20 Nov 2024
D-0044-2025Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Exelan Pharmaceuticals, NDC 76282-0478-90N/AClass IIOngoing20 Nov 2024

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2024
319
Share of these events in Class II
71%
Product records in this event
2Median of the firm: 2
Events of the firm on the register
13

Other events of the firm

Other FDA enforcement events of Cipla USA, Inc.
InitiatedProduct (first record)TypeClassRecords
29 Jun 2026Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India;DrugClass II3
16 Mar 2026Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, DrugClass II3
13 Mar 2026Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle, Single dose only, Rx Only, DrugClass II2
18 Feb 2026Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, MaDrugClass III2
2 Jan 2026Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, ManufacturDrugClass II1
22 Dec 2025Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine StreDrugClass III1
14 Nov 2025Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 IndependeDrugClass II3
24 Oct 2025Lanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack carton, Rx Only, Manufactured by: Invagen PDrugClass II2
24 Jul 2025Albuterol Sulfate, Inhalation Aerosol, 90 mcg, 200 metered Inhalations, NET CONTENT 6.7 g, Manufactured by: Cipla Ltd, IDrugClass III1
30 Jun 2025Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured byDrugClass II1

Cipla USA, Inc.: all 13 events

Official channels

Cite this page

Recall Register. FDA enforcement event 95611. https://recallregister.com/fda/ii/95611/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: USA nationwide.
What quantity of product is in FDA event 95611?
The event has 2 product records. The first record gives this quantity: 1,875 boxes (cipla and exlan)
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2024 have the same class?
71% of the 319 drug events that started in 2024 are in Class II.